Dosing & Uses
Alopecia Areata
Pending FDA approval for treatment of hair loss due to alopecia areata
Alopecia Areata
Pending FDA approval for treatment of hair loss due to alopecia areata in adults and adolescents aged ≥12 years
<12 years: Safety and efficacy not established
Pharmacology
Mechanism of Action
Dual inhibitor of the TEC family (ie, 5 nonreceptor protein tyrosine kinases [Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk]) of tyrosine kinases and Janus kinase 3 (JAK3)
TEC kinase inhibitor; TEC kinases participate in signal transduction to promote immunological function; inhibition of TEC kinases reduce T cell and NK cell cytolyic function
JAKs pathways inhibitor; JAK consists of a group of intracellular tyrosine kinases that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function
Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity including gene expression; ritlecitinib modulates the signaling pathway at the point of JAKs, preventing STATs phosphorylation and activation
